The Economic Burden of Hepatitis A, B, and C in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shon, Changwoo | - |
dc.contributor.author | Choi, Hyung-Yun | - |
dc.contributor.author | Shim, Jae-Jun | - |
dc.contributor.author | Park, So-Youn | - |
dc.contributor.author | LEE, KYUNG SUK | - |
dc.contributor.author | Yoon, Seok-Jun | - |
dc.contributor.author | Oh, In-Hwan | - |
dc.date.accessioned | 2022-07-15T19:04:02Z | - |
dc.date.available | 2022-07-15T19:04:02Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2016-01 | - |
dc.identifier.issn | 1344-6304 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155275 | - |
dc.description.abstract | The prevalence of hepatitis in South Korea is relatively high compared to that in other high-income countries. For this reason, viral hepatitis infection not only affects the population’s health, but also impacts national healthcare costs. This study was performed in order to estimate the individual economic costs of the hepatitis A, B, and C viruses as well as to determine, using nationally representative data, the trends in South Korea with respect to these viruses during the 2008-2011 period. The study found that the prevalence of hepatitis A had decreased, but those of hepatitis B and C had increased overall. The mortality rate of hepatitis C was higher than that of the other two types. The mortality rate of hepatitis B had changed little, whereas that of hepatitis C had risen. The total cost of hepatitis A had decreased, from US $62.2 million to US $45.7 million, although a notable exception occurred in 2009, when the cost was US $126.6 million. Conversely, the total cost of hepatitis B had increased rapidly during the same period, from US $501.4 million to US $607.8 million. Finally, the total cost of hepatitis C had also increased from US $63.9 million to US $90.7 million. The direct costs of hepatitis A, B, and C were estimated to account for approximately 35.5z, 46.6z, and 58.0zof the total, respectively. These findings demonstrate the economic burden associated with hepatitis A, B, and C, and demonstrate the need to establish an effective prevention and management policy for future planning in South Korea. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATL INST INFECTIOUS DISEASES | - |
dc.title | The Economic Burden of Hepatitis A, B, and C in South Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | LEE, KYUNG SUK | - |
dc.identifier.doi | 10.7883/yoken.JJID.2014.499 | - |
dc.identifier.scopusid | 2-s2.0-84955112046 | - |
dc.identifier.wosid | 000369353600004 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF INFECTIOUS DISEASES, v.69, no.1, pp.18 - 27 | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF INFECTIOUS DISEASES | - |
dc.citation.title | JAPANESE JOURNAL OF INFECTIOUS DISEASES | - |
dc.citation.volume | 69 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 18 | - |
dc.citation.endPage | 27 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | NATIONAL-HEALTH | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | COSTS | - |
dc.identifier.url | https://www.jstage.jst.go.jp/article/yoken/69/1/69_JJID.2014.499/_article | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.